Health Economics›Hodgkin lymphoma nodular lymphocyte-predominant›Maintenance after upfront therapy

Maintenance after upfront therapy

Hodgkin lymphoma nodular lymphocyte-predominant · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~20.3 mo	—	~4	~R 208 PFS proxy · indirect	17

1 of 1 regimen shown